AnaptysBio Inc.

21.66-0.0600-0.28%Vol 94.88K1Y Perf 26.33%
Apr 19th, 2021 14:10 DELAYED
BID21.60 ASK21.66
Open21.57 Previous Close21.72
Pre-Market- After-Market-
 - -%  - -
Target Price
25.00 
Analyst Rating
Hold 3.00
Potential %
16.17 
Finscreener Ranking
★★★     50.62
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     56.94
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.90
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap592.75M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
35.29 
Earnings Date
5th May 2021

Today's Price Range

21.1722.23

52W Range

13.9235.85

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
4.07%
1 Month
-2.03%
3 Months
-16.81%
6 Months
-9.80%
1 Year
26.33%
3 Years
-76.26%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANAB21.66-0.0600-0.28
AAPL134.670.51000.38
GOOG2 300.823.06000.13
MSFT258.93-1.8100-0.69
XOM56.09-0.5700-1.01
WFC44.260.42000.96
JNJ162.450.21000.13
FB301.92-4.2600-1.39
GE13.39-0.0100-0.04
JPM153.25-0.0500-0.03
Financial StrengthValueIndustryS&P 500US Markets
19.90
20.00
0.00
0.00
-368.30
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-409.20
-406.20
-561.70
-18.46
RevenueValueIndustryS&P 500US Markets
60.00M
2.19
91.84
12.57
Earnings HistoryEstimateReportedSurprise %
Q04 20201.941.20-38.14
Q03 2020-0.77-0.87-12.99
Q02 2020-0.75-0.79-5.33
Q01 2020-0.64-0.3053.12
Q04 2019-1.27-0.7540.94
Q03 2019-1.12-1.15-2.68
Q02 2019-0.93-0.894.30
Q01 2019-0.75-0.82-9.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.71-12.70Negative
6/2021 QR-0.2563.24Positive
12/2021 FY-3.11-25.91Negative
12/2022 FY-3.32-48.21Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.71
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume94.88K
Shares Outstanding27.37M
Trades Count1.68K
Dollar Volume10.74M
Avg. Volume524.94K
Avg. Weekly Volume238.24K
Avg. Monthly Volume243.67K
Avg. Quarterly Volume523.74K

AnaptysBio Inc. (NASDAQ: ANAB) stock closed at 21.72 per share at the end of the most recent trading day (a -1.59% change compared to the prior day closing price) with a volume of 258.12K shares and market capitalization of 592.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 89 people. AnaptysBio Inc. CEO is Hamza Suria.

The one-year performance of AnaptysBio Inc. stock is 26.33%, while year-to-date (YTD) performance is 1.02%. ANAB stock has a five-year performance of %. Its 52-week range is between 13.92 and 35.85, which gives ANAB stock a 52-week price range ratio of 35.29%

AnaptysBio Inc. currently has a PE ratio of -30.40, a price-to-book (PB) ratio of 1.53, a price-to-sale (PS) ratio of 9.19, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -4.48%, a ROC of -20.25% and a ROE of -4.76%. The company’s profit margin is -18.46%, its EBITDA margin is -406.20%, and its revenue ttm is $60.00 Million , which makes it $2.19 revenue per share.

Of the last four earnings reports from AnaptysBio Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.71 for the next earnings report. AnaptysBio Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for AnaptysBio Inc. is Hold (3), with a target price of $25, which is +16.17% compared to the current price. The earnings rating for AnaptysBio Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AnaptysBio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AnaptysBio Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.51, ATR14 : 2.30, CCI20 : 26.77, Chaikin Money Flow : -0.05, MACD : -1.76, Money Flow Index : 52.63, ROC : 7.37, RSI : 35.93, STOCH (14,3) : 67.64, STOCH RSI : 0.89, UO : 49.50, Williams %R : -32.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AnaptysBio Inc. in the last 12-months were: Eric J. Loumeau (Option Excercise at a value of $140 200), Eric J. Loumeau (Sold 10 000 shares of value $350 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

AnaptysBio Inc.

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

CEO: Hamza Suria

Telephone: +1 858 362-6295

Address: 10421 Pacific Center Court, San Diego 92121, CA, US

Number of employees: 89

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

News

Stocktwits